CPH to expand US footprint after USOTC listing
5 minute read
Creso Pharma Ltd (ASX:CPH) announced today that it has successfully completed a dual listing in the US and will commence trading in the region when the market opens US time (around 7.30pm this evening AEST).
The company is trading on the US OTCQB under the code COPHF.
The listing gives CPH greater exposure to a deeper capital market as well as greater access and liquidity for North American investors. Further to this, it provide additional opportunities to attract institutional and retail investors and for CPH to expand its investor base in the US.
The listing follows enormous interest from a large range of US investors as CPH has gradually built up a presence in the cannabis and psychedelics markets.
A US listing will allow CPH to fast track its move into psychedelics as the company looks to close out its acquisition of privately owned Halucenex Life Sciences.
Halucenex recently entered into a consultancy agreement with leading US-based scientific consultancy HeteroGeneity, LLC to progress a US market entry strategy for the potential use and licensing of its botanical psilocybin products and compounds.
Halucenex is focused on progressing clinical trials to research the efficacy of psilocybin to treat and alleviate Treatment Resistant Depression in individuals suffering from PTSD and other mental illnesses.
The company’s Phase II clinical trials will test the efficacy of psilocybin on the treatment of PTSD. Halucenex recently expanded the recruitment of its phase II clinical trial to include participants that have not served in the military or undertaken roles as first responders who are suffering from Treatment-Resistant Post Traumatic Stress Disorder (PTSD).
The PTSD market is valued at US$10.5 billion by 2025. This market could increase substantially if the user base extends beyond veterans.
One thing the OTC Dual Listing will provide CPH with in relation to psychedelics is greater exposure for clinical studies with universities, hospitals and research centres.
Halucenex has access to one of the largest supplies of synthetic psilocybin in Canada. Its short-term focus is to become a clinical drug pipeline provider.
The acquisition delivers CPH several multiple near-term catalysts:
- Entrance into a new, and potentially highly lucrative industry vertical, with additional potential future revenue streams in mental health.
- Licensing deals in North America and more broadly
- Clinical trials with a broadened scope in universities, hospitals and research centres
This move comes amid continued upturn in cannabis and psychedelics sectors.
A major legislative shift on cannabis in the US has drastically increased demand in the region, most notably with the Marijuana Opportunity Reinvestment and Expungement (MORE) Act being introduced to Congress, which would eliminate the federal ban on cannabis.
The dual listing provides easier comparisons to US and Canadian listed peers operating in the cannabis and psychedelic medicines sectors
Non-executive Chairman Adam Blumenthal commented, “The cannabis and psychedelic medicines sectors continue to gain considerable momentum.
Recent regulatory shifts have left the Company in a favourable position and Creso is well placed to become a global leader across both sectors.”
Fast tracking in the USA
In what is a major development for CPH, Halucencex is fast tracking its go to market strategy in California.
This comes after the recent passing of Senate Bill 519 through the California State Senate, which if signed into law, would make a wide range of psychedelic substances including psilocybin legal to use and possess for adults over the age of 21.
The law is designed to combat growing mental health issues in the US and would mean amore health-focused approach to the use of psychedelic compounds to address this current mental health crisis.
To remove the stigma around psychedelics as a medical alternative, the law would also expunge prior criminal offences for use and possession.
If the bill passes as expected, it would open the doors for Halucenex to accelerate its development plan.
The market for PTSD therapeutics is expected to grow to US$10.5 billion by 2025, but this could increase substantially if the user base extended beyond veterans.
Mental illness in Canada more broadly has an economic burden of C$51 billion per annum, highlighting the large market opportunity for Halucenex and Creso Pharma.
CPH can also fast track its cannabis sales
While sales continue to grow through CPH’s wholly-owned subsidiary Mernova Medicinal Inc., it could see sales boosted further after it announced this week that North American partner, ImpACTIVE has finalised approval for CPH products to be stocked with America’s largest pharmacy chain, CVS Pharmacy.
CVS has outlets throughout the US. It is owned by CVS Health and is currently the largest pharmacy chain in the United States by number of locations. The group operates 9,900 retail locations in 49 states, as well as stores in the District of Columbia and Puerto Rico.
The deal could open up a market expected to be valued at US$22BN by 2022 and C$220M in Canada.
What to expect next from CPH
Here’s what we expect to happen next :
- Approval process for additional products underway – Creso to leverage development to progress agreements for its own range of CBD-based products
- Creso Pharma to assist ImpACTIVE with business development initiatives in the US to drive sales growth
- Both parties continue to collaborate on product development initiatives
- ImpACTIVE and Creso will target other large retail outlets via the RangeMe platform. Buyers from other large US retailers including Walgreens, Whole Foods, PetoCo, Target, GNC and Safeway amongst others.
- Creso Pharma is also working with ImpACTIVE to progress a number of new products, including topical rollers and creams containing only CBD, as well as THC and CBD combinations. The launch of these products is scheduled for the coming months with development currently in the final stages.
The OTC listing is a major milestone for CPH and we expect to see further sales growth in the cannabis space, as well as several catalysts over the next few weeks and months including the completion of the acquisition of Halucenex.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.